Biomarker guided therapy in triple-negative breast cancer: Clinical role of ctDNA and PD-L1
Journal of Oncology Pharmacy Practice · 19.11.2026
DOI: 10.1177/10781552261507625 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology Pharmacy Practice, online erschienen am 19.11.2026. Verfasst von Sateesha Shivally Boregowda und 6 weiteren Autor:innen. Die Arbeit nennt 74 Literaturangaben.
Abstract (Originalsprache)
Objective Triple-negative breast cancer (TNBC) is a biologically heterogeneous breast cancer subtype characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 (HER2), limiting targeted treatment options and contributing to poor clinical outcomes. This review summarizes the pathological features of TNBC and highlights the theranostic potential of circulating tumour DNA (ctDNA) and programmed death-ligand 1 (PD-L1) as biomarkers for precision oncology. Data Sources Relevant literature on TNBC, ctDNA, and PD-L1 was reviewed, focusing on their molecular characteristics, detection technologies, clinical applications, pivotal clinical trials, and challenges associated with clinical translation. Data Summary ctDNA enables minimally invasive, real-time molecular profiling for detecting tumor-specific genetic alterations, monitoring treatment response, assessing minimal residual disease, and identifying disease recurrence. PD-L1 is a key immune biomarker that predicts responsiveness to immune checkpoint inhibitors. Landmark clinical trials, including KEYNOTE-355, KEYNOTE-522, IMpassion130, IMpassion131, c-TRAK-TN, and BRE12-158, demonstrate that PD-L1-guided immunotherapy improves patient selection and clinical outcomes, whereas ctDNA-guided surveillance facilitates early detection of molecular relapse and risk-adapted therapeutic intervention. Emerging biomarker-driven combination strategies integrating immunotherapy with targeted therapies further support personalized treatment approaches. Despite these advances, challenges related to assay sensitivity, tumor heterogeneity, and biomarker standardization remain. Conclusions ctDNA and PD-L1 have evolved into clinically meaningful theranostic biomarkers that support patient stratification, treatment selection, and disease monitoring in TNBC. Continued validation through prospective clinical trials and standardized biomarker assessment is essential for their routine implementation in precision oncology and for improving patient outcomes.
Zitieren
APA
Boregowda, S. S., Chowdappa, G., Jayaramu, R. A., Divyasree, B., Bhoomika, B., Rajesh, S., & Jothi, B. J. (2026). Biomarker guided therapy in triple-negative breast cancer: Clinical role of ctDNA and PD-L1. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552261507625
Vancouver
Boregowda SS, Chowdappa G, Jayaramu RA, Divyasree B, Bhoomika B, Rajesh S, et al. Biomarker guided therapy in triple-negative breast cancer: Clinical role of ctDNA and PD-L1. Journal of Oncology Pharmacy Practice. 2026. doi:10.1177/10781552261507625
BibTeX
@article{Boregowda2026,
author = {Boregowda, Sateesha Shivally and Chowdappa, Gokul and Jayaramu, Rajamma Abburu and Divyasree, B.G. and Bhoomika, B and Rajesh, S and Jothi, B Jeeva},
title = {Biomarker guided therapy in triple-negative breast cancer: Clinical role of ctDNA and PD-L1},
journal = {Journal of Oncology Pharmacy Practice},
year = {2026},
doi = {10.1177/10781552261507625}
}
EUVIMED